PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

STEMCELL Technologies Launches Innovative Products to Support CAR T Cell Research - STEMCELL Technologies, Inc. announces the launch of ImmunoCult™ Human T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium - ImmunoCult.com / Stemcell.com
STEMCELL Technologies Launches Innovative Products to Support CAR T Cell Research

 

NewswireToday - /newswire/ - Vancouver, British Columbia, Canada, 2015/06/30 - STEMCELL Technologies, Inc. announces the launch of ImmunoCult™ Human T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium - ImmunoCult.com / Stemcell.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

STEMCELL Technologies, Inc. announces the launch of ImmunoCult™ Human T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium to support T cell researchers in their goal to develop CAR T cell immunotherapeutics. The products provide significant benefits compared to existing technologies.

ImmunoCult™ Human T Cell Activators (immunocult.com) are soluble reagents that elicit robust activation and expansion of T cells and are highly shelf-stable. The Activator reagents are optimized for use with the xeno- and serum-free ImmunoCult™-XF T Cell Expansion Medium. Together, ImmunoCult™ T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium promote a streamlined workflow for the ex vivo activation and expansion of human T cells.

“We are uniquely poised to facilitate the development of cell therapies with our technology. We have been in this market for a long time, and many of our products are considered the gold standard,” said Dr. Allen Eaves, CEO and President of STEMCELL Technologies. “By enabling our customers to do research, knowing they can count on the quality and consistency of our products, we truly consider ourselves to be scientists helping scientists.”

ImmunoCult™ Human T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium build on STEMCELL’s existing portfolio of products to support T cell research, including the EasySep™ product line for immunomagnetic isolation of T cells. The new ImmunoCult™ products are currently for research use and STEMCELL is looking for partners to develop them for clinical applications.

About STEMCELL Technologies

As Scientists Helping Scientists, STEMCELL Technologies (stemcell.com) is committed to providing high-quality cell culture media, cell isolation products and accessory reagents for life science research. Driven by science and a passion for quality, STEMCELL Technologies provides over 2000 products to more than 70 countries worldwide. Our specialty cell culture reagents, instruments and tools are designed to support science along the basic to translational research continuum.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


STEMCELL Technologies Launches Innovative Products to Support CAR T Cell Research

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

STEMCELL Technologies | ImmunoCult™ Human
Publisher Contact: Hannah Lee - Stemcell.com 
604-484-4594 marketing[.]stemcell.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)